Axonis snags $115M to test oral drugs for epilepsy and neuropathic painnews2024-10-30T10:00:24+00:00October 30th, 2024|Endpoints News|
Zurzuvae won’t be developed for major depression, Sage saysnews2024-10-29T21:33:24+00:00October 29th, 2024|Endpoints News|
Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’news2024-10-29T20:05:18+00:00October 29th, 2024|Endpoints News|
Following March inspection, Novo Nordisk’s semaglutide manufacturing facility cited by FDAnews2024-10-29T19:38:06+00:00October 29th, 2024|Endpoints News|
What would RFK Jr. do on healthcare? Trump ally’s FDA plans raise alarmnews2024-10-29T19:21:34+00:00October 29th, 2024|Endpoints News|
FDA again questions Lexicon diabetes drug ahead of adcommnews2024-10-29T18:32:24+00:00October 29th, 2024|Endpoints News|
Coya shares sink on Phase 2 Alzheimer’s data for deprioritized drugnews2024-10-29T18:26:15+00:00October 29th, 2024|Endpoints News|
Novartis expands Scemblix label to first-line CML patientsnews2024-10-29T18:10:50+00:00October 29th, 2024|Endpoints News|
Shionogi touts topline data for Covid-19 antiviral for post-exposure treatmentnews2024-10-29T17:49:42+00:00October 29th, 2024|Endpoints News|
MilliporeSigma invests €70M to triple ADC manufacturing at US site news2024-10-29T17:25:48+00:00October 29th, 2024|Endpoints News|
